KADIMA SUN
INNOVATION
Kadima Sun provides strategic advisory services to corporate leadership teams, boards, and institutional investors navigating complex decisions where behavioral dynamics, market perception, and organizational psychology are as consequential as the financials.
Our advisory practice is built on the same analytical foundation as our investment research: a rigorous understanding of how cognitive bias, narrative distortion, and emotional decision-making shape outcomes. Whether helping a CEO craft a credible turnaround narrative, advising a board through a crisis, or providing institutional investors with differentiated research on companies they own, our work begins with the same question: where is human behavior distorting the outcome, and what can be done about it?
Experience
Over the past decade our Managing Partner has done extensive consulting work – including serving as an innovation & healthcare expert through leading global expert networks including GLG, Guidepoint, Atheneum, Coleman, AlphaSights, and many more – supporting project work directly for numerous public and private companies (especially within biotech/pharma) and also many of the consulting and advisory firms they employ.
Who We Work With
Corporate leadership teams facing strategic inflection points, activist pressure, narrative challenges, or operational transitions where market perception and internal alignment are both at stake.
Boards of directors evaluating CEO performance, capital allocation strategy, governance risk, or stakeholder misalignment, and looking for an independent analytical voice that combines financial rigor with behavioral insight.
Institutional investors seeking differentiated research on companies in their portfolio, particularly in situations where consensus may be driven more by narrative than by fundamentals.
What We Bring
Every engagement is grounded in our proprietary Emotional Quotient Financial Analysis (EQFA™), a structured diagnostic that maps where behavioral forces are shaping decisions, distorting perceptions, or creating blind spots. We combine this with deep fundamental research and monitoring across all stakeholders regarding shifts in sentiment, tone, language patterns, and overall decision-making signals.
Our core advisory capabilities include crisis management, strategic positioning, investor relations strategy, organizational alignment, due diligence (both quantitative and qualitative), and the suite of proprietary analytical frameworks described on the pages that follow.
Every market is rational. Until it isn’t. And it’s never rational for the reasons people think.
The EQFA™ is a structured diagnostic that maps the cognitive biases and emotional patterns driving decision-making inside companies, across investor bases, and throughout markets. It identifies where human behavior, not fundamentals, is setting the price.
We apply this to every company we cover. Every management team. Every investor consensus. Because the most dangerous assumption in finance isn’t a bad model. It’s the belief that the people using the model are thinking clearly.
At Kadima Sun, we isolate the behavioral forces that distort capital allocation, strategic execution, and market pricing: anchoring, loss aversion, overconfidence, herding, narrative bias, and the reflexive tendency to mistake conviction for evidence. We then measure how deeply these patterns are embedded in the decision architecture of the companies and markets we analyze.
Each assessment is built across a defined framework:
Rational Baseline ← Behavioral Distortion → Emotional Price
We define the decision a rational actor would make given the same information, the behavioral patterns pulling the actual decision off course, and the emotional premium or discount the market is currently assigning, along with the catalysts that expose it.
We combine deep behavioral research with AI-enabled monitoring to track sentiment shifts, language patterns, and decision-making signals in real time. Our monitoring capability uses natural language processing applied to earnings calls, investor communications, analyst reports, and public filings to detect shifts in tone, confidence, and framing that precede changes in strategy or market positioning. This is not generic sentiment analysis. It is a structured, thesis-driven monitoring system calibrated to the specific behavioral patterns we are tracking for each company.
This analysis is used to identify when management teams are making decisions driven by bias rather than strategy, to detect when consensus is built on narrative momentum rather than fundamental support, to provide institutional investors with a behavioral edge that reveals what others feel but cannot articulate, and to help leadership teams recognize and correct the emotional blind spots that erode long-term value.
Outcome: A disciplined, evidence-based view of the human forces shaping price, and the moments when emotion, not analysis, is in control.
Every stock has a price. Not every stock deserves it.
We build a savage “Short Thesis” analysis for every company we cover. Even the ones we love. Especially the ones we love. Because if the thesis can survive its own destruction, it deserves conviction. If it can’t, we want to know first.
We approach from a neutral standpoint or even positive and build from the ground up a rigorous Short Thesis. This is a conviction-grade thesis built on forensic fundamental analysis. It identifies companies where the gap between narrative and reality has become unsustainable, and where catalysts exist to close it.
At Kadima Sun, we isolate the structural vulnerabilities that bull-cases depend on but rarely stress-test: deteriorating unit economics, governance misalignment, unsustainable capital structures, and narratives that have outrun execution. We then identify the specific catalysts most likely to force a repricing.
The Framework
Bull Narrative ← Pressure Points → Repricing Catalysts
For each company, we define the assumptions the current valuation requires to be true, the fundamental evidence that challenges those assumptions, and the catalysts (earnings, regulatory, competitive, or structural) most likely to break consensus.
We combine deep fundamental research with AI-enabled monitoring to track deterioration in real time and calibrate conviction as conditions evolve.
Outcome: High-conviction short theses built with institutional discipline, and differentiated, non-consensus research for hedge funds and active managers.
Every company has a few key factors that determine its success. But one of those factors matters more than the rest. We call that the Achilles Point.
At Kadima Sun, we identify the five most critical drivers of a company’s fundamentals and stock performance. Among these, we isolate the single most influential factor that ultimately shapes how the business performs and how the market values it.
Once identified, we map each factor across a spectrum:
Worst Case ← Current Position → Best Case
What We Deliver
For each company, we define where it stands today on the factors that matter most, the steps required to move toward best-case outcomes, and the early signals that indicate movement in either direction.
We use a combination of deep fundamental research and AI-enabled monitoring to track real-time data and determine which way the company is trending.
This analysis informs investment decisions, helps leadership teams understand how their actions impact market perception and long-term value, and provides a clear roadmap for strengthening fundamental performance.
Outcome: A focused, evidence-based view of what matters most, and what to do next.
Every company faces a mix of near-term challenges, emerging risks, and strategic decisions that shape its future. The 5-5-5 Analysis clarifies all three.
It distills the most important issues into a simple, actionable framework used by institutional investors and leadership teams to understand what matters now, and what will matter next.
How It Works
At Kadima Sun, we identify the five key current problems influencing performance and perception, the five forward risks that are building beneath the surface, and the five recommended actions that can most effectively reset the narrative and strengthen long-term value.
Each element is mapped with clear context:
Current Problems ← Strategic Position → Forward Risks & Actions
We define the issues already weighing on valuation, the risks not yet fully priced in by the market, and the steps required to address both with clarity and credibility.
We combine deep fundamental research with real-time monitoring to understand how sentiment, execution, and competitive dynamics are trending.
Outcome: A concise, investor-grade view of present challenges, future risks, and the highest-impact actions to take next.
Every company has stakeholders. Few have alignment.
The Mission Statement is a unifying declaration of what the company exists to do, built not from the top down but from the full landscape of the people who depend on it, invest in it, and execute it every day.
The Five Stakeholder Groups
At Kadima Sun, we analyze the five groups whose goals must converge for a company to move with clarity and conviction:
- Customers, Clients & End Users / the people the business ultimately serves.
- Investors, Shareholders & Stakeholders / the people funding the future.
- Employees / the people building it.
- Partners / the people extending its reach.
- C-Suite & Executives / the people steering the ship.
We identify what each group is looking for from the company, where those goals align, where they conflict, and where the common thread lives.
From that analysis, we craft a single, unifying mission statement that is short, clear, and impossible to misunderstand. It answers one question: what are we doing here?
No jargon. No aspiration dressed as strategy. Just a plain declaration that every stakeholder, from the boardroom to the front line, can read, remember, and pull in the same direction.
Outcome: A mission statement built on evidence, not ego, designed so that everyone in the organization knows exactly what they are working toward and why it matters to the people they serve.
Every company knows what it does. Very few can articulate why.
The Passion Statement is the driving force behind the mission, a clear, uncompromising answer to one question: why do we do what we do?
Going Deeper
At Kadima Sun, we analyze the same five stakeholder groups, but this time we go deeper. We examine what is actually driving behavior and decision-making across each group. Not what they say motivates them. What actually does.
- Customers, Clients & End Users / the people the business ultimately serves.
- Investors, Shareholders & Stakeholders / the people funding the future.
- Employees / the people building it.
- Partners / the people extending its reach.
- C-Suite & Executives / the people steering the ship.
And sometimes, the drivers are the problem.
Maybe the C-suite is optimizing for stock compensation instead of long-term value. Maybe employees are grinding without purpose. Maybe the investor base is chasing a narrative the company never intended to build. When the drivers are misaligned, or wrong entirely, performance suffers, culture erodes, and the market eventually notices.
We identify where the driving forces are healthy, where they are distorted, and where they need to be corrected. From that analysis, we craft a single passion statement that is short, clear, and grounded in truth: a declaration of purpose that realigns every stakeholder around the real reason the company exists.
This is not inspiration for a wall plaque. It is a course correction.
Outcome: A passion statement that tells every stakeholder, from the boardroom to the front line, not just what they are building, but why it matters. When the “why” is right, the “what” follows.
Real World Case Study (Anonymized)
Review of Predictions & Outcome
Composite case study based on recent healthcare company crisis
Context
At the beginning of the crisis year, our internal framework signaled multiple red flags for critical company fundamentals, as well as material future potential problems. We generated an investment proposal identifying a publicly traded healthcare company — one transitioning from a legacy therapy franchise toward a recently commercialized advanced therapy platform — as being in a state of existential crisis that the market had not yet appropriately priced.
At the time, consensus sentiment was cautious-to-negative but not catastrophic. The equity had already declined meaningfully from its peak but retained a market capitalization implying a viable recovery path.
Our view was sharply different: we assessed that the company faced a set of self-reinforcing structural impairments — not a temporary setback — and that consensus was materially underestimating the severity, duration, and compound nature of the problems. We identified five unresolved legacy issues and ten forward-looking risks.
The Core Argument
The thesis rested on four interlocking claims:
- 1. Safety-driven label restriction would be permanent, not temporary. A series of serious adverse events in a vulnerable patient population would result in durable label narrowing, monitoring burdens, and reputational damage that would not recover on management’s projected timeline.
- 2. Revenue would deteriorate far beyond what guided figures implied. Total company revenue would appear resilient due to royalty income from an out-licensed legacy asset and milestone payments from a co-development agreement, but the newly launched advanced therapy’s commercial trajectory would reveal a structural collapse when viewed in isolation.
- 3. The competitive window was closing faster than the company could recover. Multiple well-funded competitors were advancing programs with differentiated safety profiles and scalable one-time manufacturing processes, threatening both the company’s legacy treatment category and its next-generation platform simultaneously.
- 4. Execution risk was acute and underappreciated. Eventually resulting in a major restructuring, a near-complete C-suite turnover, and a CEO departure created operational fragility precisely when the company needed flawless execution.
Price target implication: We identified the equity as likely to materially re-price lower toward a range consistent with survival, not recovery — a base case of modest cash flows from a declining franchise, with binary upside optionality dependent on several independent favorable events occurring simultaneously.
How We Score Our Own Work
Rear-View Issues: 5 of 5 Unresolved
| # | Issue Identified | Status at Review | Outcome |
|---|---|---|---|
| 1 | Advanced therapy safety events — serious adverse events in a vulnerable patient sub-population | Additional serious adverse events confirmed; label permanently narrowed; mandatory patient registry and boxed warning imposed. | ✓ VALIDATED |
| 2 | Severely damaged regulator relationship following a public dispute | Relationship remains strained; a regulatory designation was withdrawn; multiple clinical holds remain in effect. | ✓ VALIDATED |
| 3 | Sharp revenue decline in the flagship product obscured by royalty income | Revenue from the launched therapy deteriorated sharply; total revenue appeared stable due to royalties masking the collapse. | ✓ VALIDATED |
| 4 | Workforce reduction creating execution risk at critical juncture | Substantial workforce reduction enacted; average management tenure fell below one year; talent erosion confirmed. | ✓ VALIDATED |
| 5 | Strategic minority investment stake likely to be liquidated at loss | Stake liquidated within the crisis year at a material loss — within the projected range. | ✓ VALIDATED |
Forward-Looking Risks: 9 of 10 Materialized
| # | Forward-Looking Risk | What Happened | Outcome |
|---|---|---|---|
| 1 | Residual regulatory skepticism | Regulatory designation withdrawn; lead application under extended review; clinical holds remain. | ✓ VALIDATED |
| 2 | Litigation risk — shareholder suits | Multiple legal exposures emerged; securities class action risk remains active. | ~ PARTIAL |
| 3 | Restrictive label & monitoring barriers | Boxed warning & monitoring imposed — more restrictive than anticipated; addressable population smaller. | ✓ VALIDATED |
| 4 | Debt maturity pressure | Addressed through a dilutive equity offering; Altman Z-Score remains in distress territory. | ~ PARTIAL |
| 5 | Pipeline concentration | The therapy and legacy franchise generate all revenue; next-gen programs remain Phase 1. | ✓ VALIDATED |
| 6 | Execution risk after restructuring | CEO replaced mid-year; Chief Commercial and Chief Medical Officer departed; leadership instability. | ✓ VALIDATED |
| 7 | Competitive threats | Multiple well-funded competitors now simultaneously threatening both categories. | ✓ VALIDATED |
| 8 | Next-gen platform delays | Programs advancing but remain early-stage; revenue contribution years away. | ~ PARTIAL |
| 9 | Reputational damage / Hesitancy | Management acknowledged communication gap; physician hesitancy confirmed to persist. | ✓ VALIDATED |
| 10 | Payer access barriers | Majority of eligible patients remain untreated; management confirmed access/hesitancy dynamics. | ✓ VALIDATED |
Intellectual honesty requires identifying not just what we got right, but what we got wrong or only partially right. There were three meaningful misses:
- Debt pressure was less acute than anticipated. We identified near-term debt maturities as likely to force distressed sales. In practice, management addressed liquidity through a dilutive equity offering. Management’s ability to access equity markets under adverse conditions was better than expected.
- Next-generation platform delays were less severe. We predicted delays consistent with operational disruption. In practice, several programs advanced on roughly their stated timelines.
- Patient litigation has not yet emerged at scale. We identified securities litigation as a forward risk. As of the review date, a formal class action has not been certified, though initial complaints are filed.
What these misses have in common: All three involved underestimating management’s ability to execute specific defensive or operational tasks even under extreme duress.
| Bull Case | Bear Case | Base Case | |
|---|---|---|---|
| Thesis | Full recovery; expanded access; next-gen validates; leadership stabilizes. | Continued erosion; competitor approvals erode share; distressed sale. | Company survives but does not recover former trajectory; modest cash flows. |
| Key Dependencies | Requires several independent events to resolve favorably simultaneously. | Requires continued compounding of failures. | Requires neither clean recovery nor collapse — simply managed decline. |
| Market Implied? | No — would require multiple re-rating events. | No — would require accelerated deterioration. | Yes — valuation consistent with survival; equity down 80%. |
Assessment: The base case has largely played out. The bull case remains theoretically open but requires multiple independent favorable events. The bear case has not accelerated beyond current pricing because management successfully accessed equity markets.
The framework held. The five-issue diagnostic and ten-risk forward model were the right analytical architecture. Identifying issues as a structured list forced precision and made scoring possible.
Leading indicators outperformed lagging ones. The most predictive signals were qualitative: the tone of the regulatory confrontation, physician hesitancy, and competitive acceleration. The quantitative signals (revenue, balance sheet) lagged by two to three quarters.
Total revenue is a misleading headline metric. The company’s total revenue grew year-over-year even as product revenue deteriorated. Analytical lesson: sequential product revenue is the only metric that matters during a crisis.
Management’s defensive execution capacity was underweighted. We underestimated the ability to execute specific defensive tasks under pressure. Future frameworks should separate ‘structural impairment’ risk from ‘operational execution’ risk.
Intellectual honesty is part of the deliverable. The value we provide is being calibrated — knowing when we are right and why, and knowing when we are wrong and why. A client who cannot see our misses cannot trust our hits.
This case study is based on a composite of real public healthcare company situations involving advanced therapy platform transitions. Specific names, dates, figures, and identifying details have been altered or blended. All views are the author's own opinions and should not be taken as investment advice.
Every advisory engagement at Kadima Sun begins with a focused diagnostic and can evolve into an ongoing relationship calibrated to the client’s needs and the complexity of the situation.
Initial Engagement
We start with a structured assessment of the situation using our proprietary frameworks. Depending on the scope, this typically involves EQFA™ diagnostic, savage “Short Thesis”, Achilles Analysis™, and/or 5-5-5 Analysis™ applied to the company, the stakeholder landscape, or the specific strategic challenge at hand. The initial engagement is designed to produce clear, actionable deliverables within 60 to 90 days: an extensive deep-dive institutional investor grade diagnostic report that identifies the core issues, maps the behavioral dynamics at play, and outlines specific recommendations with actions that can begin being implemented immediately to fully remediate negative fundamentals and also negative emotional quotient (EQ) perceptions.
Ongoing Advisory
For clients facing sustained complexity (activist situations, multi-quarter turnarounds, leadership transitions, or ongoing investor relations challenges), we offer a retained advisory relationship. In this model, we provide continuous monitoring, regular reassessment of the behavioral landscape, and real-time counsel as conditions evolve. We serve as an independent analytical voice that complements internal teams without replacing them.
Research Engagements
For institutional investors, we provide targeted research on specific companies or situations using our full analytical framework. These engagements are typically project-based and focused on delivering a differentiated perspective that challenges or validates the investor’s existing thesis.
What Clients Can Expect
Direct access to senior-level thinking from the first conversation. We do not hand off work to junior teams. Every deliverable reflects the same analytical rigor and behavioral insight that defines our investment research. We are candid, independent, and focused entirely on getting to the right answer, even when the right answer is uncomfortable.
We work with a small number of clients at any given time. This is deliberate. The quality of our work depends on depth, not volume.